YS110
YS110 is a humanized anti-CD26 (DPP4) IgG1 monoclonal antibody. YS110 induces CD26 nuclear translocation through the caveolin pathway. YS110 inhibits the proliferation of tumor cell by delaying G2/M cell cycle transition. YS110 inhibits the infection of Middle East respiratory syndrome coronavirus (MERS CoV) by blocking the binding of MERS CoV S1 to CD26. YS110 can be used for researches on cancer or infection such as Malignant Mesothelioma and MERS[1][2][3].
Product Specifications
CAS Number
1656248-21-3
UNSPSC
12352203
Target
Dipeptidyl Peptidase; ERK; p38 MAPK
Related Pathways
MAPK/ERK Pathway; Metabolic Enzyme/Protease; Stem Cell/Wnt
Applications
COVID-19-anti-virus
Field of Research
Cancer; Infection
References & Citations
[1]Hayashi M, et al. A humanized anti-CD26 monoclonal antibody inhibits cell growth of malignant mesothelioma via retarded G2/M cell cycle transition. Cancer Cell Int. 2016 Apr 30;16:35. |[2]Yamada K, et al. Nuclear localization of CD26 induced by a humanized monoclonal antibody inhibits tumor cell growth by modulating of POLR2A transcription. PLoS One. 2013 Apr 29;8 (4) :e62304.|[3]Ohnuma K, et al. Inhibition of Middle East respiratory syndrome coronavirus infection by anti-CD26 monoclonal antibody. J Virol. 2013 Dec;87 (24) :13892-9.
Shipping Conditions
Room temperature
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Isoform
DPP-4; p38 MAPK
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
